vs
Side-by-side financial comparison of Summit Therapeutics Inc. (SMMT) and Vir Biotechnology, Inc. (VIR). Click either name above to swap in a different company.
Summit Therapeutics Inc. produced more free cash flow last quarter ($-30.4M vs $-167.9M).
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
SMMT vs VIR — Head-to-Head
Income Statement — Q3 FY2024 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $240.0K |
| Net Profit | $-56.3M | $-163.1M |
| Gross Margin | — | — |
| Operating Margin | — | -72267.9% |
| Net Margin | — | -67975.4% |
| Revenue YoY | — | -89.9% |
| Net Profit YoY | -164.5% | 23.7% |
| EPS (diluted) | $-0.08 | $-1.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $240.0K | ||
| Q2 25 | — | $1.2M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | — | $12.4M | ||
| Q3 24 | $0 | $2.4M | ||
| Q2 24 | — | $3.1M | ||
| Q1 24 | — | $56.4M | ||
| Q4 23 | — | $16.8M |
| Q3 25 | — | $-163.1M | ||
| Q2 25 | — | $-111.0M | ||
| Q1 25 | — | $-121.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-56.3M | $-213.7M | ||
| Q2 24 | — | $-138.4M | ||
| Q1 24 | — | $-65.3M | ||
| Q4 23 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | 99.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 97.9% | ||
| Q2 24 | — | 98.3% | ||
| Q1 24 | — | 99.9% | ||
| Q4 23 | — | 95.2% |
| Q3 25 | — | -72267.9% | ||
| Q2 25 | — | -9754.3% | ||
| Q1 25 | — | -4602.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -9718.7% | ||
| Q2 24 | — | -5158.7% | ||
| Q1 24 | — | -142.0% | ||
| Q4 23 | — | — |
| Q3 25 | — | -67975.4% | ||
| Q2 25 | — | -9139.9% | ||
| Q1 25 | — | -3989.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -8979.7% | ||
| Q2 24 | — | -4500.1% | ||
| Q1 24 | — | -115.8% | ||
| Q4 23 | — | — |
| Q3 25 | — | $-1.17 | ||
| Q2 25 | — | $-0.80 | ||
| Q1 25 | — | $-0.88 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.08 | $-1.56 | ||
| Q2 24 | — | $-1.02 | ||
| Q1 24 | — | $-0.48 | ||
| Q4 23 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $486.9M | $497.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $437.9M | $796.1M |
| Total Assets | $502.9M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $497.8M | ||
| Q2 25 | — | $598.7M | ||
| Q1 25 | — | $790.9M | ||
| Q4 24 | — | $901.0M | ||
| Q3 24 | $486.9M | $909.0M | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B | ||
| Q4 23 | — | $1.5B |
| Q3 25 | — | $796.1M | ||
| Q2 25 | — | $947.5M | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | $437.9M | $1.2B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.5B | ||
| Q4 23 | — | $1.6B |
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $502.9M | $1.5B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B | ||
| Q4 23 | — | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-30.3M | $-167.6M |
| Free Cash FlowOCF − Capex | $-30.4M | $-167.9M |
| FCF MarginFCF / Revenue | — | -69952.9% |
| Capex IntensityCapex / Revenue | — | 132.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-87.8M | $-824.0M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-167.6M | ||
| Q2 25 | — | $-120.2M | ||
| Q1 25 | — | $-78.1M | ||
| Q4 24 | — | $-446.4M | ||
| Q3 24 | $-30.3M | $-171.5M | ||
| Q2 24 | — | $-77.8M | ||
| Q1 24 | — | $-109.4M | ||
| Q4 23 | — | $-778.8M |
| Q3 25 | — | $-167.9M | ||
| Q2 25 | — | $-122.8M | ||
| Q1 25 | — | $-79.7M | ||
| Q4 24 | — | $-453.7M | ||
| Q3 24 | $-30.4M | $-174.2M | ||
| Q2 24 | — | $-78.5M | ||
| Q1 24 | — | $-111.3M | ||
| Q4 23 | — | $-800.4M |
| Q3 25 | — | -69952.9% | ||
| Q2 25 | — | -10111.8% | ||
| Q1 25 | — | -2630.1% | ||
| Q4 24 | — | -3666.2% | ||
| Q3 24 | — | -7321.3% | ||
| Q2 24 | — | -2553.3% | ||
| Q1 24 | — | -197.4% | ||
| Q4 23 | — | -4767.7% |
| Q3 25 | — | 132.1% | ||
| Q2 25 | — | 209.1% | ||
| Q1 25 | — | 53.7% | ||
| Q4 24 | — | 59.0% | ||
| Q3 24 | — | 116.3% | ||
| Q2 24 | — | 21.7% | ||
| Q1 24 | — | 3.3% | ||
| Q4 23 | — | 128.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
